Dopamine Receptors and Parkinson's Disease

Abstract EN

Parkinson's disease (PD) is a progressive extrapyramidal motor disorder.

Pathologically, this disease is characterized by the selective dopaminergic (DAergic) neuronal degeneration in the substantia nigra.

Correcting the DA deficiency in PD with levodopa (L-dopa) significantly attenuates the motor symptoms; however, its effectiveness often declines, and L-dopa-related adverse effects emerge after long-term treatment.

Nowadays, DA receptor agonists are useful medication even regarded as first choice to delay the starting of L-dopa therapy.

In advanced stage of PD, they are also used as adjunct therapy together with L-dopa.

DA receptor agonists act by stimulation of presynaptic and postsynaptic DA receptors.

Despite the usefulness, they could be causative drugs for valvulopathy and nonmotor complication such as DA dysregulation syndrome (DDS).

In this paper, physiological characteristics of DA receptor familyare discussed.

We also discuss the validity, benefits, and specific adverse effects of pharmaceutical DA receptor agonist.